Crohn’s Disease - Drug Pipeline Landscape, 2023
Description
Crohn’s Disease - Drug Pipeline Landscape, 2023
Crohn’s disease is a type of inflammatory bowel disease and is a chronic disease that causes inflammation, swelling and irritation in digestive tract. Crohn’s disease most commonly occurs in the small intestine and the colon. It can affect any part of your gastrointestinal (GI) tract, from the mouth to the anus.
The exact cause of Crohn’s disease is unknown. Risk factors of developing the condition, including autoimmune disease, genetic causes, and smoking.
Crohn’s disease patients may experience symptoms like diarrhea, fever, fatigue, reduced appetite and weight loss, inflammation of skin, eyes and joints, inflammation of the liver or bile ducts, kidney stones, iron deficiency (anemia).
Diagnosis tests of Crohn’s disease include blood test, stool test, colonscopy, computed tomography CT scan, upper gastrointestinal GI endoscopy, and GI exam.
Treatment of Crohn’s disease include medications like anti-inflammatory drugs, immune system suppressors, biologics, antibiotics and other medications. Nutrition therapy and surgery can also be suggested for the treatment by the healthcare provider.
Report Highlights
Global Insight Service’s, Crohn’s Disease - Drug Pipeline Landscape, 2022 report provides an overview of the Crohn's disease pipeline drugs. This report covers detailed insights on Crohn’s Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Crohn’s Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Crohn’s disease is a type of inflammatory bowel disease and is a chronic disease that causes inflammation, swelling and irritation in digestive tract. Crohn’s disease most commonly occurs in the small intestine and the colon. It can affect any part of your gastrointestinal (GI) tract, from the mouth to the anus.
The exact cause of Crohn’s disease is unknown. Risk factors of developing the condition, including autoimmune disease, genetic causes, and smoking.
Crohn’s disease patients may experience symptoms like diarrhea, fever, fatigue, reduced appetite and weight loss, inflammation of skin, eyes and joints, inflammation of the liver or bile ducts, kidney stones, iron deficiency (anemia).
Diagnosis tests of Crohn’s disease include blood test, stool test, colonscopy, computed tomography CT scan, upper gastrointestinal GI endoscopy, and GI exam.
Treatment of Crohn’s disease include medications like anti-inflammatory drugs, immune system suppressors, biologics, antibiotics and other medications. Nutrition therapy and surgery can also be suggested for the treatment by the healthcare provider.
Report Highlights
Global Insight Service’s, Crohn’s Disease - Drug Pipeline Landscape, 2022 report provides an overview of the Crohn's disease pipeline drugs. This report covers detailed insights on Crohn’s Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Crohn’s Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
237 Pages
- 1. Introduction
- 1.1 Crohn’s Disease – Pipeline Drugs, 2022-Coverage
- 2. Disease Overview – Crohn’s Disease
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Crohn’s Disease – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2022
- 3.3 Products under Development by Companies, 2022
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 Brazikumab
- 5.1.2 budesonide
- 5.1.3 Cx601
- 5.1.4 Etrasimod
- 5.1.5 Etrolizumab
- 5.1.6 Filgotinib
- 5.1.7 Guselkumab
- 5.1.8 Metronidazole
- 5.1.9 Mirikizumab
- 5.1.10 Ontamalimab
- 5.1.11 Ozanimod
- 5.1.12 Ozanimod
- 5.1.13 RHB-104
- 5.1.14 Upadacitinib (ABT-494)
- 5.1.15 Ustekinumab
- 5.1.16 Vedolizumab SC
- 5.2 Clinical Stage Drugs-Phase II
- 5.2.1 ABBV-154
- 5.2.2 Alequel
- 5.2.3 AVB-114
- 5.2.4 AVTX-002
- 5.2.5 BI 706321
- 5.2.6 BT-11 1
- 5.2.7 Deucravacitinib
- 5.2.8 Drug for Crohns Disease
- 5.2.9 E6011
- 5.2.10 EcoActive
- 5.2.11 MORF-057
- 5.2.12 MT-1303
- 5.2.13 Obefazimod
- 5.2.14 Ossium vBM-MSC
- 5.2.15 PF-06651600
- 5.2.16 PRA023 IV
- 5.2.17 QBECO
- 5.2.18 Remestemcel-L
- 5.2.19 SGX-203
- 5.2.20 SHR0302
- 5.2.21 Spesolimab
- 5.2.22 STAT-201
- 5.2.23 TAK-018
- 5.2.24 Vedolizumab IV (Pediatric)
- 5.3 Clinical Stage Drugs-Phase I
- 5.3.1 AGMB-129
- 5.3.2 ALLO-ASC
- 5.3.3 Nivolumab
- 5.3.4 Thetanix
- 5.3.5 UC-MSCs
- 5.4 Clinical Stage Drugs-Phase 0
- 5.4.1 CD7 CAR T-cells
- 5.4.2 MB-102
- 5.5 Early Stage Drugs-IND/CTA Filed
- 5.5.1 Foralumab
- 5.5.2 IL-10 Inducer
- 5.6 Early Stage Drugs-Preclinical
- 5.6.1 5-HT7 Antagonists
- 5.6.2 ACT-101
- 5.6.3 AIB-301
- 5.6.4 AMTX-100
- 5.6.5 APPL-001
- 5.6.6 Brilacidin
- 5.6.7 CLS-001
- 5.6.8 Drug for Crohns Disease
- 5.6.9 Drug for Crohns Disease
- 5.6.10 Drug for Crohns Disease
- 5.6.11 Drug for Crohns Disease
- 5.6.12 Drug for Crohns Disease
- 5.6.13 Drug for Crohns Disease
- 5.6.14 EB1004
- 5.6.15 EB1010
- 5.6.16 ExoFlo
- 5.6.17 Fat-derived Mesenchymal Allogenic Mesenchymal Troncal Cells
- 5.6.18 FIN-525
- 5.6.19 FW-CD
- 5.6.20 GT-2108
- 5.6.21 IMX-120
- 5.6.22 IntenCell
- 5.6.23 MAK11049
- 5.6.24 OTL-104
- 5.6.25 PLM-301
- 5.6.26 PR600
- 5.6.27 PR600
- 5.6.28 RNX-041
- 5.6.29 RXC008
- 5.6.30 stempeucel
- 5.6.31 T-cell vaccine
- 5.6.32 TEV-48574
- 5.6.33 TJC0434
- 5.6.34 TR8
- 5.7 Early Stage Drugs-Discovery
- 5.7.1 ARZ-003
- 5.7.2 ARZ-005
- 5.7.3 ARZC-001
- 5.7.4 CVT12011965
- 5.7.5 JAK Inhibitor
- 5.7.6 MAdCAM targeted DK4
- 5.7.7 Navacims
- 5.7.8 Oral Neuregulin-4
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 4D Pharma Plc
- 9.2 AbbVie
- 9.3 Abivax SA
- 9.4 Aclaris Therapeutics Inc
- 9.5 AgomAb Therapeutics NV
- 9.6 AIBIOS Co Ltd
- 9.7 Alpha Cancer Technologies Inc
- 9.8 Amytrx Therapeutics Inc
- 9.9 Anterogen Co., Ltd.
- 9.10 Artizan Biosciences Inc
- 9.11 AstraZeneca
- 9.12 Atlantic Healthcare Plc
- 9.13 Avalo Therapeutics Inc
- 9.14 Avexegen Therapeutics Inc
- 9.15 Avobis Bio, LLC
- 9.16 Boehringer Ingelheim
- 9.17 Bristol-Myers Squibb
- 9.18 CELLnLIFE Inc
- 9.19 Cellularity
- 9.20 CJ Bioscience
- 9.21 Comera Life Sciences
- 9.22 CryoCord Sdn Bhd
- 9.23 CVasThera
- 9.24 Deka Biosciences Inc
- 9.25 Direct Biologics, LLC
- 9.26 Dr. Falk Pharma GmbH
- 9.27 EA Pharma Co., Ltd
- 9.28 Eden Biologics Inc
- 9.29 Eli Lilly and Company
- 9.30 Enterome Bioscience SA
- 9.31 Enzo Biochem Inc
- 9.32 Exeliom Biosciences SAS
- 9.33 Finch Therapeutics Group Inc
- 9.34 First Wave BioPharma Inc
- 9.35 Galapagos NV
- 9.36 Giiant Pharma Inc
- 9.37 HAV Vaccines Ltd
- 9.38 Hoffmann-La Roche
- 9.39 Immix BioPharma Inc
- 9.40 Innovation Pharmaceuticals Inc
- 9.41 Instituto de Investigación Sanitaria de
- 9.42 Intralytix, Inc
- 9.43 Janssen Research & Development, LLC
- 9.44 Landos Biopharma Inc.
- 9.45 Lumen Bioscience Inc
- 9.46 MAKScientific LLC
- 9.47 MediBeacon
- 9.48 Mesoblast, Inc.
- 9.49 Metacrine Inc
- 9.50 Mitsubishi Tanabe Pharma Corporation
- 9.51 Morphic Therapeutic Inc
- 9.52 Orchard Therapeutics Plc
- 9.53 Ossium Health, Inc
- 9.54 Parvus Therapeutics Inc
- 9.55 PeLeMed Co Ltd
- 9.56 Pfizer
- 9.57 Praeventix LLC
- 9.58 Prometheus Biosciences, Inc.
- 9.59 Qu Biologics Inc.
- 9.60 RedHill Biopharma Limited
- 9.61 Redx Pharma Plc
- 9.62 Regentys Corp
- 9.63 Reistone Biopharma Company Limited
- 9.64 Reponex Pharmaceuticals AS
- 9.65 S.L.A. Pharma AG
- 9.66 Soligenix Inc
- 9.67 Statera Biopharma Inc
- 9.68 Stempeutics Research Pvt Ltd
- 9.69 Synlogic Inc
- 9.70 TaiwanJ Pharmaceuticals Co Ltd
- 9.71 Takeda
- 9.72 Teva Branded Pharmaceutical Products R&D, Inc.
- 9.73 Tiziana Life Sciences Plc
- 9.74 TRACT Therapeutics Inc
- 9.75 Trio Medicines Ltd
- 9.76 Yake Biotechnology Ltd.
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2.1 Clinical Trial Details – Brazikumab /AstraZeneca
- Table 2.2 Clinical Trial Details – budesonide/Dr. Falk Pharma GmbH
- Table 2.3 Clinical Trial Details – Cx601/Takeda
- Table 2.4 Clinical Trial Details – Etrasimod/Pfizer
- Table 2.5 Clinical Trial Details – Etrolizumab/Hoffmann-La Roche
- Table 2.6 Clinical Trial Details – Filgotinib/Galapagos NV
- Table 2.7 Clinical Trial Details – Guselkumab /Janssen Research & Development, LLC
- Table 2.8 Clinical Trial Details – Metronidazole /S.L.A. Pharma AG
- Table 2.9 Clinical Trial Details – Mirikizumab/Eli Lilly and Company
- Table 2.10 Clinical Trial Details – Ontamalimab/Takeda
- Table 2.11 Clinical Trial Details – Ozanimod/Bristol-Myers Squibb
- Table 2.12 Clinical Trial Details – Ozanimod/Celgene
- Table 2.13 Clinical Trial Details – RHB-104/RedHill Biopharma Limited
- Table 2.14 Clinical Trial Details – Upadacitinib (ABT-494)/AbbVie
- Table 2.15 Clinical Trial Details – Ustekinumab/Janssen Research & Development, LLC
- Table 2.16 Clinical Trial Details – Vedolizumab SC/Takeda
- Table 2.17 Clinical Trial Details – ABBV-154/AbbVie
- Table 2.18 Clinical Trial Details – AVTX-002/Avalo Therapeutics Inc
- Table 2.19 Clinical Trial Details – BI 706321/Boehringer Ingelheim
- Table 2.20 Clinical Trial Details – BT-11 1/Landos Biopharma Inc.
- Table 2.21 Clinical Trial Details – Deucravacitinib/Bristol-Myers Squibb
- Table 2.22 Clinical Trial Details – E6011 /EA Pharma Co., Ltd
- Table 2.23 Clinical Trial Details – EcoActive /Intralytix, Inc
- Table 2.24 Clinical Trial Details – MT-1303/Mitsubishi Tanabe Pharma Corporation
- Table 2.25 Clinical Trial Details – Ossium vBM-MSC/Ossium Health, Inc
- Table 2.26 Clinical Trial Details – PF-06651600 /Pfizer
- Table 2.27 Clinical Trial Details – PRA023 IV/Prometheus Biosciences, Inc.
- Table 2.28 Clinical Trial Details – QBECO/Qu Biologics Inc.
- Table 2.29 Clinical Trial Details – Remestemcel-L/Mesoblast, Inc.
- Table 2.30 Clinical Trial Details – SHR0302/Reistone Biopharma Company Limited
- Table 2.31 Clinical Trial Details – Spesolimab/Boehringer Ingelheim
- Table 2.32 Clinical Trial Details – TAK-018/Takeda
- Table 2.33 Clinical Trial Details – Vedolizumab IV (Pediatric)/Takeda
- Table 2.34 Clinical Trial Details – ALLO-ASC/Anterogen Co., Ltd.
- Table 2.35 Clinical Trial Details – Nivolumab/Bristol-Myers Squibb
- Table 2.36 Clinical Trial Details – UC-MSCs/CryoCord Sdn Bhd
- Table 2.37 Clinical Trial Details – CD7 CAR T-cells/Yake Biotechnology Ltd.
- Table 2.38 Clinical Trial Details – MB-102 /MediBeacon
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Crohn’s Disease, 2022
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Crohn’s Disease, 2022
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Crohn’s Disease, 2022
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Crohn’s Disease, 2022
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Crohn’s Disease, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
